Biocross is involved in a new clinical study

Biocross is involved in a new clinical study

Biocross is involved in a new multicenter study in which 17 hospitals from Spain, France, and Belgium are participating. The objective is to recruit over 500 patients, classified as healthy individuals or patients with AD, mild cognitive impairment, or other...
A diagnosis against forgetting

A diagnosis against forgetting

The biotechnology spin-off Biocross is developing a laboratory test for accurate identification of Alzheimer’s disease patients. Biocross researchers are working on developing a multiparameter system, as it seems clear that a single marker is unlikely to...